RxDoctor Payments Data

Thomas Kenny, MD

Otolaryngology · Dakota Dunes, SDNPI 1386694354

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,642 of the $2,516 with a category attached, or 65.3%. 14 manufacturers reported payments, led by Medical Device Business Services, Inc. at 43.0% of the total. Reporting peaked in 2020 at $1,150 and has fallen 64.1% since, to $413 in 2025.

$2,516in general payments, 2019–2025

Across 76 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$1K
  • Sanofi$385
  • Aerin Medical Inc.$271
  • GSK$128
  • Smith+Nephew$121
  • Acclarent, Inc$121
  • plus $409 from 8 others

What the payments were for

  • Travel & lodging$87435%
  • Food & beverage$1,64265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,516 in reported general payments places this provider in the 75th percentile of 39 otolaryngology providers in South Dakota.

See all otolaryngology providers in South Dakota

Medicare billing

Part B allowed, 2024
$117,111
Medicare patients
311
Services billed
1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate11$6,218
Ipratropium Bromide37$754
Azelastine Hcl39$393
Fluticasone Propionate27$254
Ciprofloxacin Hcl16$196
Omeprazole12$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$16$6,21811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 otolaryngology providers in South Dakota.

Other otolaryngology in Dakota Dunes

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →